It is estimated that four million people in the United Kingdom have either osteoarthritis or rheumatoid arthritis. With the extension in lifespan seen in recent decades, the number is thought to be increasing. Many of the above will be treated with non-steroidal anti-inflammatory drugs. Lithium has been proven to be useful in the prophylaxis of affective disorders. It is also used in refractory depression and mania and has been advocated in those with aggressive outbursts. McCreadie et all found it being taken by 0-77/1,000 people in south west Scotland. Extrapolated to the United Kingdom this would mean lithium is taken by approximately 40,000 patients. With the increasing use of non-steroidal anti-inflammatory drugs and lithium, the possibility of interactions are more likely. Seven reports of patients taking both agents detail interactions leading to a toxic elevation of the serum lithium level. The non -steroidal anti -inflammatory drugs previously implicated have been piroxicam,2 3 4 mefanamic acid,5 6 indomethacin7 and phenylbutazone.8 We have recently observed two patients with affective disorders who were maintained on lithium carbonate but then developed lithium toxicity following inadvertent prescription of non -steroidal anti -inflammatory drugs by their general practitioner. REPORTS CASE 1. A 73-year-old widow had been suffering from annual episodes of endogenous depression for five years. She had previously responded to tricyclic anti -depressants and electroconvulsive therapy. Her physical health had been excellent except for menorrhagia which required hysterectomy at age 52, and osteo -arthritis. She had no renal or hepatic impairment and was on no medication except that for her psychiatric condition. Maintenance treatment with antidepressant drugs proved unsatisfactory because of tremor and tinnitus. Lithium carbonate (Priadel, Delandale) 400 mg at night was commenced in July, 1987. 
Lithium / NSAID interacturi At this dose she achieved serum lithium concentrations in the range 0 5-0 6 mmol /1 and remained clinically euthymic. In March, 1988 Delandale) 400 mg twice daily, pimozide (Orap, Janssen) 12 mg four times daily, ibuprofen 400 mg three times daily and thyroxine 50 mcg daily. She used no other medications. Episodically she would complain of unsteadiness and tremor. On these occasions her serum lithium concentration, which was usually in the range 0 7-0 09 mmol /1, would be above 1 * 2 mmol /1. Initially it was felt this might be related to erratic use of her medication. Serum urea, electrolytes, creatinine and liver function tests had been stable over several years and remained within normal laboratory values despite fluctuating serum lithium levels. There was no clinical or laboratory evidence of salt or water depletion. Though the dose of neuroleptic was high, this had been found necessary to control her illness and her tremor was not parkinsonian. It was decided to give out her tablets on a daily rather than a weekly basis, but despite this her serum lithium concentration rose from 0 9 mmol / 1 (on 7.9.87) to 1 5 mmol/l (on 23.10.87). We then suspected that varying use of ibuprofen was causing these fluctuations. Her serum lithium was stabilised at 0 7 mmol / I on 400 mg lithium carbonate per day. Withdrawal of ibuprofen was then followed by a fall in serum lithium to 0-4 mmol / 1 after one week, and re -introduction was followed by a rise of serum lithium to 0 7 mmol / I. DISCUSSION Lithium carbonate is an effective compound in the prophylaxis of unipolar and bipolar affective disorders but it has a narrow therapeutic index and drug interactions can cause fatalities. It is now clear but perhaps not widely recognised that some non -steroidal anti-inflammatory drugs can elevate serum lithium concentrations into the toxic range and this report adds ibuprofen to the list. Even patients maintained at the lower end of the therapeutic range for serum lithium may present with toxic symptoms or fluctuating lithium concentrations. Given the increasing use of lithium carbonate for recurrent affective disorder in older The Ulster Medical Journal patients, who are more likely to be prescribed non -steroidal anti-inflammatory drugs, this interaction requires greater attention. Furthermore it is particularly general practitioners who need to be aware of this as it is they, rather than the psychiatrist, who are most likely to prescribe one of these analgesic agents for a transient or newly emergent inflammatory problem. Our first case in particular highlights this problem, and the patient developed signs of toxicity that continued for some time before the next appointment at the hospital. We would advise all doctors to consult the relevant section on drug interactions in the British National Formulary before prescribing any adjunctive medication to a patient on lithium. Certain drugs, such as piroxicam, may be more potent than others. The mode of interaction is unclear but may be related to renal prostaglandin function.6'8 Nonsteroidal anti-inflammatory agents act to reduce prostaglandin synthesis, by inhibiting the cyclo -oxygenase enzyme system. Sodium excretion is subsequently reduced in the kidney and this lowers lithium clearance.9 Other non -steroidal anti-inflammatory drugs implicated also have powerful prostaglandin inhibitory action.'0 The implication of ibuprofen, which is now available without prescription, leads to further concern.
Dr Kelly is currently supported by a Clinical Research Fellowship from the Department of Health and Social Services, Northern Ireland.
